Targeted Sequencing for Faster Tumor Mutational Burden Assessment

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for evaluating tumor mutational burden, such as whole exome sequencing, are costly, time-intensive, and not widely available, making them unsuitable for routine clinical practice, and existing genomic profiling techniques fail to exclude functional alterations affecting cell division, growth, or survival.

Innovation Solution

A targeted next-generation sequencing approach is used to profile a small fraction of the genome or exome, focusing on a predetermined set of genes associated with cancer, to determine mutation load by excluding functional and germline alterations, and providing a surrogate for total mutation load through hybrid capture-based methods.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If whole exome sequencing is used to measure total mutation burden, then measurement precision is improved, but cost, time consumption, and technical complexity increase

Engineering Contradiction:
Improvemutation burden measurementVSAvoidsequencing complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The patent divides the genome into specific subgenomic intervals (hotspot regions) rather than sequencing the entire exome. This segmentation approach focuses sequencing efforts on predetermined cancer-associated genes and regions, reducing the overall complexity while maintaining measurement precision for mutation burden assessment.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent applies local quality by concentrating sequencing depth and coverage on specific subgenomic intervals that are most relevant for mutation burden measurement. Rather than uniform coverage across the entire exome, the method enhances local quality in critical regions while reducing coverage elsewhere, optimizing both precision and resource efficiency.

Inventive Principle:
Principle #3Local quality

2Measurement precision

If whole exome sequencing is used to measure total mutation burden, then measurement precision is improved, but turnaround time increases

Engineering Contradiction:
Improvemutation burden measurementVSAvoidturnaround time
Core Design Contradiction:
Measurement precisionVSLoss of time

Solution Approach 1:

By segmenting the sequencing target into specific subgenomic intervals rather than the entire exome, the patent reduces the total sequencing workload and data processing requirements. This enables faster turnaround time while preserving measurement precision through focused coverage of mutation-relevant regions.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent applies partial action by sequencing only the necessary subgenomic intervals required for accurate mutation burden measurement, rather than performing complete exome sequencing. This partial sequencing approach achieves sufficient precision for clinical decision-making while significantly reducing turnaround time.

Inventive Principle:
Principle #16Partial or excessive action

3Measurement precision

If whole exome sequencing is used to measure total mutation burden, then measurement precision is improved, but cost increases

Engineering Contradiction:
Improvemutation burden measurementVSAvoidsequencing cost
Core Design Contradiction:
Measurement precisionVSQuantity of substance

Solution Approach 1:

The patent segments the sequencing target into essential subgenomic intervals, reducing the quantity of sequencing reactions, reagents, and computational resources required. This segmentation maintains measurement precision by focusing on mutation-rich regions while lowering overall testing costs.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent changes the parameter of sequencing coverage from comprehensive exome-wide coverage to focused subgenomic interval coverage. This parameter change reduces the total amount of sequencing performed, thereby reducing cost while preserving the precision needed for mutation burden measurement through targeted deep sequencing of critical regions.

Inventive Principle:
Principle #35Parameter changes

4Productivity

If targeted sequencing of subgenomic intervals is performed, then productivity is improved, but measurement precision may be compromised

Engineering Contradiction:
Improvetesting throughputVSAvoidmutation burden measurement
Core Design Contradiction:
ProductivityVSMeasurement precision

Solution Approach 1:

The patent segments the genome into comprehensive subgenomic intervals that collectively cover all known cancer-associated genes and mutation hotspots. This segmentation enables high productivity through streamlined sequencing while maintaining measurement precision by ensuring complete coverage of all clinically relevant mutation regions.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent creates a universal panel of subgenomic intervals that serves multiple functions: it enables high-throughput sequencing for productivity, maintains comprehensive cancer gene coverage for measurement precision, and provides actionable mutation data for clinical decision-making. This multi-functional design resolves the contradiction between speed and accuracy.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach offers a faster, more manageable, and cost-effective method for evaluating mutation load, enabling simultaneous detection of actionable alterations for targeted therapies and predicting immune therapy responses, with clinically actionable predictors of treatment outcomes.

Implementation Method 1

contacting the library with a bait set to provide selected tumor members by hybridization, thereby providing a library catch

Methodology Applied
Scientific EffectHybridization:

Data Source

PatentEP3423828B1Methods and systems for evaluating tumor mutational burden
Publication Date: 2025.08.27 FOUNDATION MEDICINE INC
  • EP3423828B1 patent drawingFigure 1A
  • EP3423828B1 patent drawingFigure 1B
  • EP3423828B1 patent drawingFigure 1C

AI summary

Methods of evaluating tumor mutational burden in a sample, e.g., a tumor sample or a sample derived from a tumor, from a subject, are disclosed.